US › Healthcare

Kamada (KMDA)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$7.23+5.24%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$54.9M

Revenue YoY

+22.7%

Net profit

$9.3M

Profit YoY

+25.6%

EPS

$0.16

EPS estimate

$0.12

Net margin

16.9%

EPS came in at 0.16 against a street estimate of 0.12 — a beat of 33.3%.

Key statistics

Market cap

$396.5M

P/E

18.1

Forward P/E

14.5

P/B

1.55

Book value

$4.66

EPS (TTM)

$0.38

Dividend yield

2.47%

52-week high

$8.96

52-week low

$6.28

50-day MA

$8.13

200-day MA

$8.01

Beta

0.20

Analyst view

Analysts rate Kamada a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $13.50.

Shareholding

Insiders

6.99%

Institutions

49.23%

Largest institutional holders

Fund	Stake
Phoenix Financial Ltd	2.87%
Renaissance Technologies Corp	1.29%
Wells Fargo & Co	1.03%
ARK Investment Management LLC	0.46%
Acadian Asset Management LLC	0.27%
Two Sigma Investments LLC	0.26%
Marshall Wace Asset Management Ltd	0.13%
Man Group PLC	0.11%

Corporate actions

Action	Detail	Date
Dividend	$0.17 / share ex-date Aug 27, 2026 · pay Sep 17, 2026	2026-08-27
Dividend	$0.25 / share ex-date Mar 23, 2026 · pay Apr 6, 2026	2026-03-23

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kamada — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.